{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":24,"n_cols":5,"rows_kept":24,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[14,2,14,3],[15,2,15,3],[19,2,19,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910797575603321"]
[null,null,"Autore",null,"Castellblanch Ramón <1948->"]
[null,null,"Titolo",null,"Driving down the cost of drugs : battling big pharma in the statehouse / / Ramón Castellblanch"]
[null,null,"Pubbl/distr/stampa",null,"Boulder, Colorado ; ; London, [England] : , : FirstForumPress, , 2012"]
[{"$nulls":4},"©2012"]
[null,null,"ISBN",null,"1-62637-336-1"]
[null,null,"Descrizione fisica",null,"1 online resource (186 p.)"]
[null,null,"Disciplina",null,"368.38/24"]
[null,null,"Soggetti",null,"Prescription pricing - California"]
[{"$nulls":4},"Prescription pricing - Maine"]
[{"$nulls":4},"Prescription pricing - Vermont"]
[{"$nulls":4},"Drugs - Prices - California"]
[{"$nulls":4},"Drugs - Prices - Maine"]
[{"$nulls":4},"Drugs - Prices - Vermont"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"Title page; copyright page; Dedication; Contents; Preface; Acknowledgments; ch1-David, Goliath, and Prescription Drugs; ch2-How Drugs Got So Expensive; Getting Patent Privileges; Making the FDA a Partner and the Rise of the Blockbusters; Fighting Government Oversight and Exploiting the Blockbusters; The Blockbusters' Toll on America; ch3-Vermont Raises the Cry; The Road to S 300; 1999; S 300; Epilogue; ch4-As Goes Maine; Maine Background; Low-cost Drugs for the Elderly; Senate Leadership Commitments to Supporting Price Controls; Leinonen; Northeast Legislators; LD 2599; Industry Response"]
[{"$nulls":4},"Public Support to the RescueKing-Pingree Negotiations; Maine Rx; PhRMA v. Concannon; Maine Rx Plus; Postscript; ch5-PhRMA Tries Stopping State Action; PhRMA Political Spending in the Early 2000s; Post-Maine Rx State and Local Legislation; PhRMA's Turn to Congress; Industry Building Its Economic Power; Advocates' Continued Fighting after Part D; ch6-So Goes California; California Overview; 1999-2003; 2004: Legislative Leadership Taking the Stage; The Rise of Tension between the Governor and Legislative Leadership; 2005; 2006; Making a Deal; Implementation Delayed"]
[{"$nulls":4},"ch7-Politically Organizing for Access to MedicinesHearing Voters' Righteous Indignation; Allying with Powerful Progressive Organizations; "]
[{"$nulls":4},"Politically Isolating the Pharmaceutical Industry; \"Framing\" after Righteous Indignation; Inferences beyond Fighting for Medicines; Implications for US Health Policy; Appendix: Useful Websites on Health Care Policy and Politics; Bibliography; Index; About the Book"]
[null,null,null,"Sommario/riassunto","How can health-access advocates beat the wealthy pharmaceutical industry, which has the biggest spending lobby in Washington? Ramón Castellblanch provides a ringside seat at the battle as he reveals how activists in Vermont, Maine, and California took on Big Pharma in their state legislatures to promote better and cheaper access to prescription drugs—and ultimately pushed Congress to enact a Medicare prescription drug benefit. He also draws lessons from these cases about the possibilities for success elsewhere in the health policy arena, highlighting the crucial role that voters' righteous indignation plays in fueling popular support for grassroots political leaders who are taking on powerful business interests."]